Detalhe da pesquisa
1.
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
Cell
; 184(15): 3949-3961.e11, 2021 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161776
2.
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
J Infect Dis
; 227(1): 23-34, 2022 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35895508
3.
Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.
Clin Infect Dis
; 75(1): e380-e388, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35219277
4.
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
N Engl J Med
; 377(3): 211-221, 2017 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28538136
5.
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Cell Metab
; 7(1): 68-78, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18177726
6.
Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection.
Open Forum Infect Dis
; 10(12): ofad598, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38111750
7.
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial.
Open Forum Infect Dis
; 10(5): ofad211, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37229174
8.
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.
Nat Commun
; 14(1): 3605, 2023 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37330602
9.
Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency.
Sci Transl Med
; 15(723): eadd4897, 2023 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37992152
10.
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
Nat Med
; 29(10): 2615-2624, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37770652
11.
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies.
mBio
; 13(6): e0169922, 2022 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36255239
12.
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
JAMA Netw Open
; 5(8): e2225411, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35969402
13.
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
Int J Infect Dis
; 122: 585-592, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35788416
14.
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
Lancet Infect Dis
; 22(10): 1444-1454, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35803290
15.
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
Br J Clin Pharmacol
; 71(3): 429-36, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21284702
16.
The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia.
Biomarkers
; 16(4): 321-33, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21417623
17.
A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.
J Clin Pharmacol
; 49(8): 937-46, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19602719
18.
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
J Clin Pharmacol
; 48(5): 592-8, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18353996
19.
Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects.
Br J Clin Pharmacol
; 66(1): 36-42, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18503607
20.
Human pharmacokinetics and interconversion of enantiomers of MK-0767, a dual PPARalpha/gamma agonist.
J Clin Pharmacol
; 47(3): 323-33, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17322144